Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 0.81 USD 1.87% Market Closed
Market Cap: 93.9m USD

Relative Value

The Relative Value of one CHRS stock under the Base Case scenario is 3.89 USD. Compared to the current market price of 0.81 USD, Coherus BioSciences Inc is Undervalued by 79%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CHRS Relative Value
Base Case
3.89 USD
Undervaluation 79%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
88
vs Industry
91
Median 3Y
1.2
Median 5Y
2.4
Industry
7.3
Forward
1.6
vs History
vs Industry
12
Median 3Y
-2
Median 5Y
-2.1
Industry
23.3
Forward
-0.7
vs History
1
vs Industry
Median 3Y
-2.1
Median 5Y
-1.6
Industry
19.8
vs History
1
vs Industry
Median 3Y
-1.5
Median 5Y
-0.6
Industry
22.6
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-1
Industry
2.7
vs History
74
vs Industry
75
Median 3Y
2.4
Median 5Y
2.5
Industry
7.6
Forward
5.4
vs History
53
vs Industry
72
Median 3Y
3.9
Median 5Y
3
Industry
9.4
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.3
Industry
4.7
Forward
-1.8
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
4.8
Forward
-1.6
vs History
1
vs Industry
Median 3Y
-3.6
Median 5Y
-3
Industry
5.3
vs History
1
vs Industry
Median 3Y
-3.6
Median 5Y
-3
Industry
3.8
vs History
74
vs Industry
60
Median 3Y
1.4
Median 5Y
3.1
Industry
5

Multiples Across Competitors

CHRS Competitors Multiples
Coherus BioSciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Coherus BioSciences Inc
NASDAQ:CHRS
93.9m USD 0.5 -0.7 -3.1 -2.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 706 744.2 -160 203.2 -194 537.7 -192 317.8
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 090.1 -533.3 -580.7 -565.3
AU
CSL Ltd
ASX:CSL
117.5B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/S Multiple
Revenue Growth P/S to Growth
US
Coherus BioSciences Inc
NASDAQ:CHRS
Average P/S: 3 064 446.2
0.5
-22%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 706 744.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 090.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.4
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Coherus BioSciences Inc
NASDAQ:CHRS
Average P/E: 34.4
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 203.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Coherus BioSciences Inc
NASDAQ:CHRS
Average EV/EBITDA: 15.7
Negative Multiple: -3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 537.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Coherus BioSciences Inc
NASDAQ:CHRS
Average EV/EBIT: 20.3
Negative Multiple: -2.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 317.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A